CJC-1295 no DAC & Ipamorelin Legal 2026 Status: Comparison Table
503B Outsourcing Facility Legal for research distribution; voluntary cGMP compliance Legal for research distribution; mandatory cGMP and batch testing Enforcement of existing cGMP standards made non-negotiable FDA registration, CoA with HPLC purity ≥98%, endot
This comparison does not assign a generated winner or score.
- 503B Outsourcing Facility
- Legal for research distribution; voluntary cGMP compliance
- Legal for research distribution; mandatory cGMP and batch testing
- Enforcement of existing cGMP standards made non-negotiable
- FDA registration, CoA with HPLC purity ≥98%, endotoxin testing, sterility validation
- Only reliably compliant pathway for interstate peptide distribution in 2026
- 503A State Pharmacy Compounding
- Legal for individual patient prescriptions under state law
- Restricted. Peptides not on 503A bulk substances list require clinical necessity documentation
- FDA interpretation removed most peptides from 503A eligibility
- Prescriber justification, adverse event reporting, state board approval
- Functionally unavailable for CJC-1295/Ipamorelin unless prescriber can document no FDA-approved alternative
- Research Chemical Vendor (Non-Registered)
- Grey-market; FDA enforcement sporadic
- Active enforcement. 150+ cease-and-desist letters issued 2024–2026
- FDA now cross-references seller websites against 503B registry
- None. Operates outside regulated framework
- High risk. Peptides may be chemically accurate but lack documentation trail required for institutional use
- International Supplier (Non-U.S.)
- Legal to import for personal research use under exemption
- Import seizures increased 340% since March 2024 under unapproved drug enforcement
- Customs and Border Protection now flags peptide shipments without institutional documentation
- Institutional affiliation proof, research protocol reference, import license
- Not viable for individual buyers. Seizure rate makes it unreliable even for legitimate research